In wild-type, CML cell lines and imatinib-resistant CML cell lines, DMP11 not only degraded the target protein BCR-ABL but also the SRC protein (Yes/Fyn/Fgr) in a time- and dose-dependent manner; when we preknocked down the fusion protein BCR-ABL, the dose-dependent inhibitory effect of DMP11 on cells disappeared, but the degradation of SRC proteins (Yes/Fyn/Fgr) was not affected. This evidence concerns the gene SRC and chronic myelogenous leukemia, BCR-ABL1 positive.